This article is more than 5 years old. Information may no longer be current.

Alimera reports 167% increase in net revenue in 2015

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alimera Sciences reported $22.4 million in consolidated net revenue in 2015, a 167% increase from $8.4 million reported in 2014, according to a press release.

Consolidated net revenue was reported at $5.8 million in the fourth quarter, a 241% increase from $1.7 million reported in the same quarter of 2014.

The revenue increases were driven by an increase in sales of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) in the U.S.

Net revenue in the U.S. was reported at $15.2 million in 2015, driven by the commercial launch and use of Iluvien by U.S. retinal physicians.

Non-GAAP adjusted net loss attributable to common stockholders was reported at $43.4 million, or $0.98 per share, in 2015 compared with $34.4 million, or $0.85 per share, in 2014.